Kornimate/medical-research-clean huggingface dataset:
endoscopic variceal ligation (evl)+ drugs versus endoscopic variceal ligation (evl) alone for secondary prophylaxis

Conditions: Portal Hypertension

Summary: background: both endoscopic variceal ligation (evl) and propranolol are valuable methods for secondary prophylaxis of variceal bleeding. addition of ismn to propranolol improves the efficacy of drug therapy. it is hypothesized that a combination of evl and portal pressure reducing drugs should significantly be better than evl alone. patients and methods: patients with history of variceal bleed were randomized to evl plus drugs (propranolol and ismn) or evl alone. evl was repeated every 3-4 weeks until variceal eradication. propranolol dose was adjusted to reduce the resting heart rate to 55 bpm. dose of ismn was 40 mg/d. primary end points were rebleed or death. secondary end points included complications of portal hypertension and the development of serious adverse effects to therapy.


Eligibility criteria:
inclusion criteria: * patients presenting to g b pant hospital, new delhi, with history of hematemesis and/or melena and proven to have esophageal varices as the bleeding source on upper gi endoscopy were included in the study. exclusion criteria: * a history of undergoing endoscopic sclerotherapy (est), evl, or cyanoacrylate injection; * a history of surgery for portal hypertension; * coexisting malignancy; * severe cardiopulmonary or renal disease; * a history of severe side-effects or contraindications to beta-blockers like bronchial asthma, uncontrolled diabetes mellitus, heart failure, peripheral vascular disease, prostatic hypertrophy, arterial hypotension (systolic blood pressure \< 100 mm hg), bradycardia (basal heart rate \<55 beats per minute), or complete heart block; and * refusal to give consent to participate in the trial.
neuro linguistic programming pain levels after cesarean delivery

Conditions: Nursing Caries; Pain, Postoperative

Summary: this study was conducted to determine the effect of neuro-linguistic programming (nlp) application on post-cesarean section pain levels.

the study was carried out between march 1 and june 1, 2021 with mothers who gave birth through cesarean section in the postpartum service of a maternity and children's hospital in the most populated city of turkey, which is located in the west. the study data consists of a total of 76 individuals, including 38 in the experimental group and 38 in the control group. in the study, the effect size was calculated as 2.22. accordingly, the power of the study, which was completed with 38 individuals in the control group and 38 in experimental group, had an effect size of 2.22, and used a significance level of 0.05, was calculated as 99.9%. the power analysis was conducted on the g\*power software package.

Eligibility criteria:
inclusion criteria: * the study included individuals who * had a cesarean section, * were at the 6th to 24th hour postpartum, * agreed to participate in the study, * had a cesarean section for the first time, * did not use patient-controlled analgesia (pca), * did not have an additional health problem that may cause pain in the postpartum period, other than cesarean incision pain, and * could speak and understand turkish. exclusion criteria: * mothers who wanted to quit on their own will at any stage after being included in the study, had verbal communication problems, had hearing or vision problems, or had previously been diagnosed with a psychiatric illness were excluded from the sample.

Keywords: nlp, cesarean section, postpartum, pain
detection of jaundice from ocular images via deep learning

Conditions: Ophthalmology; Artificial Intelligence; Hepatobiliary Disease

Summary: our study presents a detection model predicting a diagnosis of jaundice (clinical jaundice and occult jaundice) trained on prospective cohort data from slit-lamp photos and smartphone photos, demonstrating the model's validity and assisting clinical workers in identifying patient underlying hepatobiliary diseases.

this study demonstrated that deep learning models could detect jaundice using ocular images in blood levels with reasonable accuracy, providing a non-invasive method for jaundice detection and recognition. this algorithm can assist clinical surgeons with daily follow-up visits and provide referral advice. it also highlights the algorithm's potential smartphone application in sizeable real-world population-based disease-detecting or telemedicine programs.

Eligibility criteria:
inclusion criteria: * the quality of slit-lamp images should be clinical acceptable. more than 90% of the slit-lamp image area, including three central regions (sclera, pupil, and lens) are easy to read and discriminate. exclusion criteria: * images with light leakage (\>10% of the area), spots from lens flares or stains, and overexposure were excluded from further analysis

Keywords: ophthalmology artificial intelligence ocualr image jaundice
hormones and social anxiety disorder treatment

Conditions: Social Anxiety Disorder

Summary: the purpose of this study is to determine whether power posing (i.e., holding poses associated with dominance and power), compared to submissive posing or rest, prior to exposure therapy for social anxiety disorder: 1) leads to a temporary increase in testosterone levels and/or 2) facilitates exposure therapy outcomes.


Eligibility criteria:
inclusion criteria: * outpatients between the ages of 18 to 70 years of age with a primary psychiatric diagnosis (designated by the patient as the most important source of current distress) of social anxiety disorder as defined by dsm-5 criteria, with fear of public speaking endorsed as a primary concern. * willingness and ability to participate in the informed consent process and comply with the requirements of the study protocol. exclusion criteria: * current use of testosterone enhancing products (i.e., gels, creams, or injections) * a lifetime history of bipolar disorder, schizophrenia, psychosis, or delusional disorders; organic brain syndrome, mental retardation or other cognitive dysfunction that could interfere with capacity to engage in therapy; a history of substance or alcohol abuse or dependence (other than nicotine) in the last 6 months. * entry of patients with other mood or anxiety disorders will be permitted in order to increase accrual of a clinically relevant sample; however in cases where sad is not judged to be the predominant disorder, participants will not be eligible. * patients with significant suicidal ideation or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention. * patients using psychotropic medication (e.g., antidepressants, anxiolytics, beta blockers) must be on a stable dose for three weeks prior to initiation of randomized treatment. * significant personality dysfunction likely to interfere with study participation. * patients with a current or past history of seizures. * any concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of the sad is excluded. prohibited psychotherapy includes cbt or psychodynamic therapy focusing on exploring specific, dynamic causes of the phobic symptomatology and providing management skills. general supportive therapy initiated \> 3 months prior is acceptable. * prior non-response to adequately delivered exposure (i.e., as defined by the patient's report of receiving specific and regular exposure assignments as part of a previous treatment). * patients with a history of head trauma causing loss of consciousness, seizure or ongoing cognitive impairment. * subjects with back pain issues or medical conditions that would make it difficult to hold posture manipulations. * insufficient command of the english language.
greek registry - familial hypercholesterolaemia

Conditions: Familial Hypercholesterolemia

Summary: familial hypercholesterolemia (fh) \[heterozygous (hefh) or homozygous fh (hofh)\] is a common genetic disorder, characterized by elevated plasma low density lipoprotein (ldl) cholesterol concentration leading (if untreated) to cholesterol deposits in the corneas, eyelids and extensor tendons, rapidly progressing vascular disease, and aortic valve disease.

in contrast, timely recognition and effective treatment of fh can result in a significant improvement in clinical outcomes. the problem is that that majority of individuals with fh are unaware of their disease, particularly that the disease remains silent for many years. in most countries around the world \<5% of individuals with fh are identified . until lately the prevalence of hefh was traditionally considered to be \~ 1:500 individuals , although clinical and genetic studies suggest that hefh affects \~ 1:200-250 individuals . thus, the aim of the hellenic college of treatment of atherosclerosis (hcat) is to 1). evaluate the prevalence of fh in greece (fhg-registry) and 2). to inform population of fh disease.

Eligibility criteria:
inclusion criteria: * both genders * \>18 years, \<80 years * door to door enrolment * eligible to sign informed consent exclusion criteria: * \ 80 years * deny to sign informed consent
does ultrasound scanning of the lumbar spine improve patient satisfaction and the ease of insertion epidurals?

Conditions: Labor Pain

Summary: ultrasound scanning of the back has been shown to increase success when used to guide epidural catheter insertion. however, this technique is not applied widely in clinical practice. stronger evidence is required to prove that it will improve the clinical experience of labour epidurals. the study hypothesis is that anesthesiologists (both residents and fellows), will have an increased rate of success and ease of insertion of labour epidural catheters, and that there will be increased patient satisfaction, if ultrasound scanning of the lumbar spine is done prior to the procedure.

studies have shown that ultrasound scanning of the lumbar spine is beneficial in certain circumstances (eg. predicted difficult epidurals). however, no large scale studies with multiple anesthesiologists performing the technique have been done to show that ultrasound scanning may be of benefit in their everyday clinical practice. this study will involve residents and fellows, each performing epidural insertions with and without the use of ultrasound scanning of the lumbar spine prior to the procedure. if the hypothesis is correct, then the use of this technique may become widespread, resulting in less complications and increased patients satisfaction.

Eligibility criteria:
for patients: inclusion criteria: * ability to speak in english * requesting epidural analgesia for labour * having easily palpable spine (clinically 'easy' back) exclusion criteria: * contraindications to epidural analgesia * patients with a history of difficult epidural insertions or spinal anesthetic * patients with a known history of back surgery * patients with known significant kyph0scoliosis for anesthesiologists: inclusion criteria: * residents and fellows training or practicing at mount sinai hospital and enrolled in either a residency or fellowship program at the university of toronto.

Keywords: epidural analgesia ultrasound training, inservice
phii one label non-comparative trial in metastatic hormone refractory prostate cancer in combination with prednisolone

Conditions: Prostatic Neoplasms

Summary: * to evaluate the overall tumor response rate in subjects with metastatic hormone refractory prostate cancer * to evaluate psa (tumor marker) response rate * to evaluate safety


Eligibility criteria:
inclusion criteria: * men with prostate adenocarcinoma with at least one metastatic lesion which is measurable and who progressed after prior hormonal therapy. exclusion criteria: * 1.body temperature \> 38 degree centigrade. * 2.prior radiotherapy to \> 25% of bone marrow. * 3.prior isotope therapy and/or brachytherapy * 4.prior gene therapy. * 5.active double cancer. * 6.known brain or leptomeningeal involvement. * 7.history of hypersensitivity reaction to drug * 8.other serious illness or medical condition * 9.subjects whom the investigators consider inappropriate from social or medical aspects.

Keywords: prostate cancer hrpc aipc hormone refractory androgen independent docetaxel taxotere prednisolone
biomarkers in predicting response to rituximab treatment in samples from patients with indolent follicular lymphoma

Conditions: Lymphoma

Summary: rationale: studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how well patients will respond to treatment. purpose: this research study is studying biomarkers in predicting response to rituximab treatment in samples from patients with indolent follicular lymphoma.

objectives: primary * genotype the full cohort of samples available from the resort clinical trial (ecog-e4402) for fcgr3a 158v/f in parallel to independently verify results. * correlate the fcgr3a 158v/f polymorphisms to response, response duration, and time to rituximab resistance. secondary * quantify copy number variation in fcgr3a in this cohort. outline: archived dna samples isolate from peripheral blood mononuclear cells and from formalin-fixed paraffin-embedded tissue samples are analyzed for fcgr3a 158v/f polymorphisms using different complementary genotyping methods. assay results are reviewed and compared with patients' outcome data.

Eligibility criteria:
disease characteristics: * diagnosed with indolent follicular lymphoma * treated on resort trial (ecog-e4402) comprising rituximab monotherapy and then randomized to rituximab maintenance therapy or retreatment with rituximab upon disease relapse * blood and tissue samples from patients available patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: recurrent grade 1 follicular lymphoma recurrent grade 2 follicular lymphoma
effectiveness of the oxford-astrazeneca covid-19 vaccine as a 2nd booster, the reforco-brazil study

Conditions: COVID-19

Summary: this study will address specific questions concerning the additional protection of the az covid-19 vaccine as a second booster dose in preventing severe covid-19 outcomes (hospitalisation, icu admission etc) and will provide data to inform covid-19 vaccine booster dose recommendations.

in brazil, second covid-19 boosters became available to specific risk groups in early 2022. by june 2022, immunocompromised individuals aged 12 years and above, individuals aged 50 years and above, and healthcare workers were eligible for a second booster. the vaccines available for second booster doses in brazil are produced by astrazeneca (az), janssen, pfizer and sinovac. while several studies have estimated absolute vaccine effectiveness (ave) or relative vaccine effectiveness (rve) of second boosters of mrna covid-19 vaccines, only a single study has, to date, estimated ave of az vaccine as a second booster dose, and no studies have estimated rve for az vaccine as a second booster dose. as the pandemic progresses, more individuals are choosing to become vaccinated (and boosted) against covid-19 and thus there is greater need to evaluate the additional protection offered by a second booster dose amongst individuals previously administered a first booster. this is particularly important in the context of waning protection of a first booster dose. the primary objective is to estimate relative vaccine effectiveness (rve) against covid-19 hospitalization of the az covid-19 vaccine as a second booster dose relative to a first booster dose only, of any covid-19 vaccine, administered at least four months ago. this study will also evaluate rve of other vaccines used in brazil as a second booster doses. the study will further evaluate rve of all vaccines (including the az-covid-19 vaccine) as a first booster dose relative to a complete primary series only, of any covid-19 vaccine administered at least four months ago."

Eligibility criteria:
inclusion criteria: * hospitalized for sars between 01 january 2022 and 31 december 2022 (population a) or hospitalised for sars between 01 august 2021 and 31 december 2022 (population b). * eligible for a second covid-19 vaccine booster dose at the time of sars hospitalization (i.e., aged 50+ or aged 18+ and either a hcw or with an ic) for second booster objectives \[population a\] or eligible for a first covid-19 vaccine booster dose at the time of sars hospitalisation (i.e., aged 18+) for first booster objectives \[population b\]. * results available for a rt-pcr and/or antigen test for sars-cov-2 conducted on a sample taken up to 14 days after symptom onset. * individuals have required matching variables (e.g. age and sex). exclusion criteria: * hospitalized for covid-19 within 3 months prior to date of current hospital admission for sars * nosocomially-acquired infection (where sars case is flagged as nosocomial and/or where symptom onset date is after hospitalisation date)

Keywords: covid-19, real-world effectiveness, chadox1 ncov-19 vaccine, second booster dose
randomized trial of outpatient vs. inpatient management of low-risk patients with upper gastrointestinal bleeding.

Conditions: Upper Gastrointestinal Bleeding

Summary: patients presenting to the emergency room with upper gastrointestinal bleeding and a glasgow blatchford score of zero will be randomly assigned to further care in the inpatient vs. outpatient setting. the hypothesis of this study is that patients who are managed as outpatients will require interventions at a rate not higher than those managed as inpatients and will have lower direct healthcare costs.


Eligibility criteria:
inclusion criteria: 1. blood urea nitrogen \< 18.2 mg/dl 2. hemoglobin ≥ 13.0 g/dl for men and ≥ 12.0 g/dl for women 3. systolic blood pressure ≥ 110 mm hg 4. heart rate \< 100 beats/min exclusion criteria: 1. inability to obtain informed consent 2. pregnancy 3. history of liver disease 4. history of heart failure 5. syncope that is temporally related to ongoing bleeding 6. melena 7. contraindication to proton pump inhibitor use 8. other conditions that necessitate inpatient evaluation. 9. inpatients with new onset of gi bleeding
acute lung injury after allogeneic transplantation - diagnosis and early treatment

Conditions: Acute Lung Injury

Summary: acute lung injury (ali) is an early complication after allogeneic transplantation causing significant mortality and morbidity. little is known on early markers and treatment of this complication. recent data (hilbert et al.) suggested a beneficial effect of non-invasive-ventilation in ali-patients immunosuppressed because a many different reasons including stem-cell transplantation. the investigators study is designed to evaluate early markers of ali after allogeneic transplantation. in case ali is documented patients are randomized to either conventional therapy (oxygen-support) or conventional therapy plus intermittent non-invasive ventilation. the hypothesis is that non-invasive ventilation improves outcome of ali after allogeneic transplantation.


Eligibility criteria:
inclusion criteria: patients undergoing allogeneic transplantation presenting with at least two of the following criteria * respiratory rate \>25 / min * oxygenation index \<300 * continuous oxygen-saturation \<92% whilst breathing room air exclusion criteria: * indication for emergency intubation * hemodynamic instability * left ventricular failure * gcs \<8 * no consent

Keywords: acute lung injury after allogeneic transplantation
prospective, longitudinal study of the natural history and functional status of patients with myotubular myopathy (mtm)

Conditions: Myotubular Myopathy

Summary: this is a prospective, non-interventional, longitudinal study of the natural history and function of approximately 60 patients with mtm from the united states, canada and europe. the duration of the study, including the enrollment period, will be 36 months. data from the study will be used to characterize the disease course of mtm and determine which outcome measures will be the best to assess the efficacy of potential therapies.

this is a prospective, non-interventional, longitudinal study of the natural history and function of patients with mtm. the study duration is 36 months. the enrollment period will be 12 months and each patient will be assessed over 24 months. data will be analyzed at baseline and annually thereafter and reports will be prepared based on these analyses. a final report will summarize findings after all patients have completed 24 months of follow-up. assessments performed in this study will be based on the age and ambulatory status of the patient. the assessments will also be adjusted to account for the variability in both phenotypes and age of the patients who may participate in this study. patients will be evaluated at baseline, month 6, month 12 and month 24. it is anticipated that approximately 60 patients from the united states, canada and europe will be included in this study.

Eligibility criteria:
inclusion criteria: * patients of any age (newborns included) may participate. * patients over 18 years of age and parent(s)/legal guardian(s) of patients \<18 years of age must provide written informed consent prior to participating in the study and informed assent will be obtained from minors at least 7 years of age when required by regulation. * mtm resulting from a mutation in the mtm1 gene. * male or symptomatic female. a symptomatic female will be defined by the motor function assessment by motor function measure (mfm) or north star ambulatory assessment (nsaa) below 80% of the total score. * willing and able to comply with all protocol requirements and procedures. exclusion criteria: * other disease which may significantly interfere with the assessment of mtm and is clearly not related to the disease. * currently enrolled in a treatment study; or treatment with an experimental therapy other than pyridostigmine.

Keywords: mtm myotubular myopathy x-linked centronuclear myopathy inherited myopathies neuromuscular diseases hypotonia genetic mutation
cognitive-behavioral treatment of attention deficit hyperactivity disorder (adhd) in college students - study 1

Conditions: ADHD

Summary: college students with adhd have significant difficulty effectively managing their time, organizing, planning, and completing their academic work. as a result, they typically have lower grade-point averages, more course failures and withdrawals, are more likely to be placed on academic probation and are less likely to graduate from college than students without adhd. the purpose of this project is to refine and test a psychological intervention on campus to help students with adhd develop these self-management skills so that they can be more successful in college and avoid these negative outcomes.

participants will be assessed pre- and post-intervention during interviews with the clinician-investigators and on several self-report questionnaires designed to assess their self-management of time, organization, and planning. feedback of the results will be discussed with them, including any recommendations for further treatment.

Eligibility criteria:
inclusion criteria: * student at the city college of new york * diagnosis of adhd, inattentive or combined subtype * in good physical health exclusion criteria: * actively abusing drugs or alcohol within the past 6 months * actively suicidal * diagnosis of borderline personality disorder * diagnosis of bipolar disorder * diagnosis of a psychotic disorder * neurological disorder (such as traumatic brain injury, brain tumor, parkinson's) * history of childhood abuse or trauma or psychiatric condition that prevents clear * confirmation of the presence of adhd in childhood * any other acute psychiatric condition (e.g. acute panic disorder, severe depression) with treatment needs that take precedence over adhd.